ライフサイエンスコーパス: parkinsonism

1 d 34 years) and labelled as having 'juvenile parkinsonism'.

2 nd 16 [3.5%] of multiple system atrophy with parkinsonism).

3 Bank criteria, without exclusion of familial parkinsonism.

4 tients with Gaucher disease with and without parkinsonism.

5 erated in cortical-basal ganglia circuits in parkinsonism.

6 he study of progressive neurodegeneration in parkinsonism.

7 ing of iMSNs characterize symptomatic rodent parkinsonism.

8 lear, is essential to understand its role in parkinsonism.

9 erturbed endosomal cargo sorting in atypical parkinsonism.

10 nition of patients with Gaucher disease with parkinsonism.

11 (DAT) cause a syndrome of infantile dystonia/parkinsonism.

12 he development of familial manganese-induced parkinsonism.

13 ulness as a diagnostic tool in patients with parkinsonism.

14 in a 6-hydroxydopamine (6-OHDA) rat model of parkinsonism.

15 ive diseases of the motor system or atypical parkinsonism.

16 eurological deficits, including dystonia and parkinsonism.

17 ltiple deletions, and altered mitophagy with parkinsonism.

18 w-up, patients were assessed for dementia or parkinsonism.

19 logous to some symptoms reported in INCL and parkinsonism.

20 ting the pathological firing associated with parkinsonism.

21 ning mitochondrial integrity and suppressing Parkinsonism.

22 erns include the potential for akathisia and Parkinsonism.

23 the majority of autosomal recessive juvenile Parkinsonism.

24 ith autosomal recessive early-onset dystonia-parkinsonism.

25 te a role for PPTg in the pathophysiology of parkinsonism.

26 rders, including cerebral palsy and juvenile parkinsonism.

27 dentified in family members with adult-onset parkinsonism.

28 at higher risk to develop neurodegenerative parkinsonism.

29 nts in our case series presented symptoms of parkinsonism.

30 e mutations to neurodegenerative early-onset parkinsonism.

31 extrapyramidal clinical disorders, including parkinsonism.

32 ity and is implicated in the pathogenesis of parkinsonism.

33 model for co-morbid depressive disorder and parkinsonism.

34 have a role in LID severity in experimental Parkinsonism.

35 have been implicated in late-onset familial parkinsonism.

36 se positron emission tomography for atypical parkinsonism.

37 c intracellular GPR37 aggregates observed in parkinsonism.

38 e most common cause of recessively inherited parkinsonism.

39 ith iron accumulation and prominent dystonia-parkinsonism.

40 ease or earlier onset spasticity followed by parkinsonism.

41 igher incidence than women for most types of parkinsonism.

42 he network, is also affected in experimental parkinsonism.

43 mal recessive juvenile-onset and young-onset parkinsonism.

44 his pathway is compromised in a rat model of Parkinsonism.

45 n some cases of frontotemporal dementia with parkinsonism.

46 syndrome of infantile/juvenile dystonia and parkinsonism.

47 gerated throughout basal ganglia circuits in parkinsonism.

48 individuals classified as having subclinical parkinsonism.

49 ning is associated with an increased risk of parkinsonism.

50 0), a gene that is associated with recessive Parkinsonism.

51 role of the lysosome in the pathogenesis of parkinsonism.

52 AP) in a cohort of patients with early-stage parkinsonism.

53 re discovered to be associated with atypical parkinsonism.

54 .0%), 1 had amyotrophic lateral sclerosis in parkinsonism (0.2%), 1 had parkinsonism secondary to sur

55 the 2000 subcohort, we observed 28 cases of parkinsonism (10 with PD) during 22,307 person-years.

56 were 128 nondemented patients with new-onset parkinsonism (104 with PD, 11 with multiple system atrop

57 nd seizures (2.8%, 0.5-5.9) and moderate for parkinsonism (11.2%, 5.3-17.1).

58 ribed signs were movement disorders, such as parkinsonism (12%) and dystonia (19%).

59 .6-22.2 and 15.0%, 12.5-17.6, respectively), parkinsonism (12.5%, 10.1-15.0), and seizures (20.3%, 17

60 , aripiprazole was also associated with more Parkinsonism (15 [17%] of 86 vs two [2%] of 81 participa

61 ssing TTBK1 and frontotemporal dementia with parkinsonism-17-linked P301L (JNPL3) tau mutant (TTBK1/J

62 severe form of SCS and controls in rates of parkinsonism (19% vs 17%; odds ratio, 1.09 [95% CI, 0.28

63 induced parkinsonism (6.6%), 11 had vascular parkinsonism (2.0%), 1 had amyotrophic lateral sclerosis

64 Among patients with incident parkinsonism, 24 (30.4%) also developed dementia (10 bef

65 ctive cohort of 60 patients with early-stage parkinsonism (39 PD, 21 AP).

66 Of 906 patients with parkinsonism, 501 were men, and the median age at onset

67 Thirty-six subjects had drug-induced parkinsonism (6.6%), 11 had vascular parkinsonism (2.0%)

68 4 years) compared to multiple system atrophy-parkinsonism (62.3 years; P < 0.001).

69 Among 542 incident cases of parkinsonism, 64 had DLB and 46 had PDD.

70 the 1990 subcohort, there were 182 cases of parkinsonism (84 of which were PD) during 57,052 person-

71 s of the disorder were identified, including parkinsonism (95.2% of patients), depression/apathy (71.

72 nit gene (ATP1A3) cause rapid-onset dystonia-parkinsonism, a rare movement disorder characterized by

73 more than 90 days, atypical or drug-induced parkinsonism, a Unified Parkinson's Disease Rating Scale

74 the clinical and pathological correlates of parkinsonism across birth cohorts in relation to critica

75 ls and extends beyond patients with onset of parkinsonism after dementia.

76 We named this disinhibition-dementia-parkinsonism-amyotrophy complex.

77 cts were classified as level I indeterminate parkinsonism and 4 more subjects as level II indetermina

78 n DCTN1; or a family history of the disease, parkinsonism and a mutation in DCTN1; or the presence of

79 Asp421Asn, in an adult male with early-onset parkinsonism and ADHD.

80 K(+)-ATPase, cause both rapid-onset dystonia parkinsonism and alternating hemiplegia of childhood.

81 Parkinsonism and attention deficit hyperactivity disorde

82 to higher MPTP doses to produce significant parkinsonism and behavioral impairments.

83 in 62 isolated individuals with early-onset parkinsonism and confirmed consanguinity followed by dat

84 ternal ophthalmoplegia (CPEO) complicated by parkinsonism and dementia.

85 n early adulthood with progressive dystonia, parkinsonism and dementia.

86 ants of the Rotterdam Study who were free of parkinsonism and dementia.

87 f each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy.

88 3,4-dihydroxyphenylalanine (DOPA)-responsive parkinsonism and drug-resistant gait and balance disorde

89 een linked to symptoms of the early onset of Parkinsonism and Dystonia.

90 of Guam is a neurodegenerative disease with parkinsonism and early-onset Alzheimer-like dementia ass

91 Autosomal recessive parkinsonism and genes implicated without significant ge

92 involved in the onset of a familial form of parkinsonism and highlight the possibility of using enha

93 3 modifies age of onset for LRRK2 Gly2019Ser parkinsonism and informs disease-relevant translational

94 displaying clinical features of early-onset parkinsonism and intellectual disability identified a ap

95 c transmission, but its role in experimental Parkinsonism and l-DOPA responses has been neglected.

96 anguage impairment and sometimes features of parkinsonism and motor neuron disease.

97 opathological subtypes: MSA with predominant parkinsonism and MSA with predominant cerebellar ataxia,

98 ive development of intention tremor, ataxia, parkinsonism and neuropsychological problems.

99 These alpha-synucleinopathies have in common parkinsonism and non-motor features including orthostati

100 le-onset movement disorder (including severe parkinsonism and nonambulation), mood disturbance, auton

101 We investigated trends in the incidence of parkinsonism and Parkinson disease (PD) by comparing dat

102 Changes over time in the incidence of parkinsonism and Parkinson disease (PD) remain uncertain

103 Our study suggests that the incidence of parkinsonism and PD may have increased between 1976 and

104 Incidence rates of parkinsonism and PD over 30 years.

105 DAT binding for differentiating symptomatic parkinsonism and relevant tremor syndromes from neurodeg

106 hydropyridine-treated macaques with advanced parkinsonism and reproducible LID received a range of na

107 Incidence of parkinsonism and specific proteinopathies.

108 One patient experienced drug-induced parkinsonism and sudden-onset dementia, while the other

109 r neuropathies, spinal muscular atrophy with parkinsonism and the later stages can resemble amyotroph

110 o screened positive to determine the type of parkinsonism and the presumed proteinopathy using specif

111 f (18)F-FDG PET for diagnostic evaluation of parkinsonism and the promising role of (18)F-FDG PET for

112 To study how glucocerebrosidase impacts parkinsonism and to evaluate new therapeutics, we genera

113 s used to identify all persons who developed parkinsonism and, in particular, DLB or PDD from 1991 th

114 tonomic failure along with motor symptoms of parkinsonism and/or cerebellar ataxia.

115 pastic paraplegia accompanied by neuropathy, parkinsonism and/or cognitive impairment.

116 istinct association profiles for symptoms of parkinsonism and/or dementia, respectively, toward the 3

117 of gait is a major risk factor for falls in parkinsonism, and a source of disability to patients.

118 derivations of this) to identify subclinical parkinsonism, and association of risk estimates with MDS

119 sease include progressive autonomic failure, parkinsonism, and cerebellar ataxia leading to significa

120 thogenesis of amyotrophic lateral sclerosis, parkinsonism, and dementia in Guamanian Chamorros.

121 of an endolysosomal genetic defect linked to Parkinsonism, and highlight the presence of alpha-synucl

122 c) Gaucher disease, two with and two without parkinsonism, and one patient with Type 2 (acute neurono

123 k for Lewy body accumulation, progression of parkinsonism, and PD, but not dementia, AD, neuritic pla

124 ; P = .004) loci were associated with global parkinsonism, and these associations remained after excl

125 nsorineural deafness, peripheral neuropathy, parkinsonism, and/or cognitive impairment, in most cases

126 nce to differentiate between PD and atypical parkinsonism (AP) in a cohort of patients with early-sta

127 are mutated in autosomal-recessive juvenile Parkinsonism (AR-JP) and work together in the disposal o

128 Autosomal-recessive juvenile Parkinsonism (AR-JP) is caused by mutations in a number

129 early onset of autosomal-recessive juvenile parkinsonism (AR-JP), although the mechanisms by which a

130 netic changes specific for X-linked dystonia-parkinsonism are common in the Philippines, the epigenet

131 esting that signs of depressive disorders in parkinsonism are related to altered stress vulnerability

132 sms by which mutations in this protein cause parkinsonism are unclear.

133 tated in 50% of autosomal recessive juvenile parkinsonism (ARJP) cases.

134 revalence and genetic causes of dystonia and parkinsonism as well as radiological findings in the con

135 everal genes whose mutation causes inherited parkinsonism, as well as risk loci for sporadic PD.

136 disease, three frontotemporal dementia with parkinsonism associated with chromosome 17, three unclas

137 nant early amnesia and behavioural change or parkinsonism associated with the 'missing' +15 mutation

138 Here, we found that the parkinsonism-associated protein DJ-1 and its bacterial h

139 The Parkinsonism-associated protein DJ-1 has been suggested

140 Recently, the Parkinsonism-associated protein DJ-1 was described in vi

141 ow this interactome is perturbed in atypical parkinsonism-associated VPS26A mutants.

142 al DA-related disorders, including infantile parkinsonism, attention-deficit/hyperactivity disorder a

143 lation of manganese or of copper can lead to parkinsonism because of dopamine deficiency.

144 y, mutations in SLC30A10 that cause familial parkinsonism blocked the ability of the transporter to t

145 gression models to compare the incidences of parkinsonism, both overall and by cause (PD and secondar

146 algorithm to classify subjects with clinical parkinsonism but uncertain diagnosis based on the expres

147 discharge before and after the induction of parkinsonism by administration of MPTP (1-methyl-4-pheny

148 e how dysregulation of their firing in early Parkinsonism can impair their effector circuits.

149 -localized manganese efflux transporter, and parkinsonism-causing mutations block its trafficking and

150 inant disorder characterized by weight loss, parkinsonism, central hypoventilation, and psychiatric d

151 of autonomic failure, levodopa-unresponsive parkinsonism, cerebellar ataxia and pyramidal symptoms.

152 rder with symptoms of autonomic failure plus parkinsonism, cerebellar ataxia, or both.

153 ommon and disabling symptom in patients with parkinsonism, characterised by sudden and brief episodes

154 sociated with a distinct form of early-onset parkinsonism characterized by rapid and severe disease p

155 idered in families where amnesia or atypical parkinsonism coexists with behavioural disturbance early

156 In this model, motor parkinsonism correlates well with the loss of nigral dop

157 ndividuals with multiple system atrophy with parkinsonism, dementia with Lewy bodies, and Parkinson d

158 sociated with amyotrophic lateral sclerosis, parkinsonism, dementia, and related neurodegenerative sy

159 were reviewed for clinical features such as parkinsonism, dementia, and vascular risk factors.

160 Parkinsonism-dementia (PD) of Guam is a neurodegenerativ

161 e cause of the amyotrophic lateral sclerosis/parkinsonism-dementia complex (ALS/PDC), or Alzheimer's

162 i of amyotrophic lateral sclerosis (ALS) and parkinsonism-dementia complex (PDC) exist in Japanese on

163 Amyotrophic lateral sclerosis/parkinsonism-dementia complex has been described in Guam

164 eurotoxins possibly responsible for atypical Parkinsonism/dementia clusters, via the consumption of e

165 The association of CPEO and parkinsonism/dementia with subclinical optic neuropathy

166 Lines generated from the patients with parkinsonism demonstrated elevated levels of alpha-synuc

167 Vanoxerine has been in clinical trials for Parkinsonism, depression and cocaine addiction but lacke

168 disorder characterised by clinical signs of parkinsonism, depression/apathy, weight loss, respirator

169 Patients with dementia diagnosis before parkinsonism diagnosis were considered to have probable

170 city of data on cognitive functioning before parkinsonism diagnosis, a stage at which patients may st

171 Patients presenting with parkinsonism dystonia or a neurotransmitter profile char

172 ort presented with classical infantile-onset parkinsonism dystonia, with one surviving into adulthood

173 ntation of early infantile-onset progressive parkinsonism dystonia.

174 nile onset (outside infancy) and progressive parkinsonism dystonia.

175 redefined extrapyramidal movement disorders (parkinsonism, dystonia, tremor, chorea, and restless leg

176 sults in rapidly progressive childhood-onset parkinsonism-dystonia with distinctive brain magnetic re

177 mp) are responsible for rapid-onset dystonia parkinsonism (DYT12).

178 es, including amyotrophic lateral sclerosis, parkinsonism, epilepsy, and hemiplegic migraine.

179 ove the diagnostic accuracy in patients with parkinsonism, even at early disease stages.

180 the proof or exclusion of neurodegenerative parkinsonism, for its early and preclinical diagnosis, a

181 Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010.

182 Patients may present with ALS, Parkinsonism, frontotemporal dementia, myopathy, Paget's

183 isease', 'Paradoxical kinesia', 'Psychogenic parkinsonism', 'Functional somatic syndromes', 'Chronic

184 Mn-induced parkinsonism generally occurs as a result of exposure to

185 analysis model to indicate that all forms of parkinsonism had elevated free-water in the substantia n

186 with Type 2 and Type 1 Gaucher disease with parkinsonism had reduced dopamine storage and dopamine t

187 rrelated the core features of DLB (dementia, parkinsonism, hallucinations, and fluctuations) with str

188 hich is mutated in some types of early-onset Parkinsonism, has been suggested as a regulator of the a

189 genetic conditions presenting with atypical parkinsonism have been described.

190 sease, only a handful of monogenic causes of parkinsonism have been identified.

191 associated with a higher hazard of incident parkinsonism (hazard ratio [HR], 1.79; 95% CI, 1.37-2.33

192 Patients with multiple system atrophy with parkinsonism (hazard ratio, 10.51; 95% CI, 2.92-37.82) h

193 oving individuals with dementia onset before parkinsonism (HR, 1.72; 95% CI, 1.28-2.27).

194 a well-known toxic agent causing symptoms of parkinsonism in employees of certain branches of industr

195 These findings suggest that the incidence of parkinsonism in general, and of PD in particular, decrea

196 f all changes specific for X-linked dystonia-parkinsonism in genomic DNA.

197 type tag for which the median onset of LRRK2 parkinsonism in GG carriers was 12.5 years younger than

198 HTRA2 and PINK1 loss of function causes parkinsonism in humans and animals.

199 he typical antipsychotic haloperidol induces parkinsonism in humans and catalepsy in rodents.

200 ss induced reversible symptoms that resemble parkinsonism in humans and in animal models raise the qu

201 ld SWI could identify prodromal degenerative parkinsonism in iRBD.

202 ify incidence cases of PD and other types of parkinsonism in Olmsted County, Minnesota, from 1976 to

203 isorder years or decades before the onset of parkinsonism in people who develop Parkinson's disease.

204 ail to excrete Mn and may develop Mn-induced parkinsonism in the absence of exposure to elevated Mn.

205 ght female predominance in the prevalence of parkinsonism in the Philippines.

206 romosome inactivation is the likely cause of parkinsonism in this heterozygous mutation carrier.

207 f PPTg in gait, developed a refined model of parkinsonism including partial loss of the PPTg with bil

208 tion is a common feature among patients with parkinsonism, including Parkinson disease (PD).

209 en implicated in neurological disorders with parkinsonism, including Parkinson's disease and Dementia

210 ssociated with an increased risk of incident parkinsonism, including probable PD.

211 y for the potential management of Mn-induced parkinsonism, including that occurring as a result of mu

212 ethyl-4-phenyl-1,2,3,6-tetrahydropyridine, a parkinsonism-inducing agent.

213 Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous

214 Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic

215 excluding non-DLB dementias, especially when parkinsonism is the only "core feature" exhibited by the

216 ly believed to be a common cause of atypical parkinsonism, is now recognised as a range of motor and

217 h experiments in humans and animal models of Parkinsonism, it is unclear how the pattern regularizati

218 c lateral sclerosis and rapid-onset dystonia parkinsonism, knowledge of their contribution to motor n

219 bilitating and often fatal form of infantile Parkinsonism known as AADC deficiency.

220 MAPT gene cause frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), characte

221 rders, including frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), which is

222 gene MAPT cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17).

223 ein bearing two frontotemporal dementia with Parkinsonism linked to chromosome 17 pathogenic mutation

224 d p.S170P), and frontotemporal dementia with parkinsonism linked to chromosome-17 (FTDP-17; n = 2; MA

225 Parkinsonism-linked mutations that weaken homodimer inte

226 ite recessive inheritance, X-linked dystonia-parkinsonism (Lubag disease) has also been described in

227 In experimental parkinsonism models, regression curves representing thes

228 (multiple-system atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C

229 (multiple-system atrophy with predominantly parkinsonism [MSA-P], n = 9), cerebellar type MSA (MSA-C

230 yndrome; they showed a combination of severe parkinsonism, near mutism, dysphagia with choking, verti

231 y), play a role in differential diagnosis of parkinsonism (not well), and investigate pathology under

232 most stringent published cut-off for subtle parkinsonism of three definitions examined (p=0.027).

233 individuals received a diagnosis of incident parkinsonism; of these, 57 (72.2%) received a diagnosis

234 o developed dementia (10 before and 14 after parkinsonism onset).

235 st-stroke movement disorders can manifest in parkinsonism or a wide range of hyperkinetic movement di

236 found in patients with rapid-onset dystonia parkinsonism or alternating hemiplegia of childhood caus

237 tcomes were a quantitative measure of global parkinsonism or component measures of bradykinesia, rigi

238 No history of parkinsonism or other neurologic disorders was reported.

239 y elevated in neurons from the patients with parkinsonism or Type 2 Gaucher disease.

240 patients manifested Perry syndrome, isolated parkinsonism, or a predominant behavioral variant of fro

241 mentia, psychiatric disturbances, associated parkinsonism, or an autosomal dominant disorder is prese

242 emiplegia of Childhood, Rapid-onset Dystonia Parkinsonism, or epilepsy.

243 nce weekly for 3 weeks to induce features of Parkinsonism, or vehicle (control).

244 Cognition indicates the probability of parkinsonism over long intervals and extends beyond pati

245 r binding and the diagnosis of nigrostriatal parkinsonism, particularly PD.

246 entia and death) as well as the mortality of parkinsonism patients in the 2 subcohorts.

247 its Sac domain was identified in early-onset parkinsonism patients.

248 Hazard ratios (HRs) for incident parkinsonism per SD decrease in global cognition, adjust

249 enes that are mutated in autosomal recessive parkinsonism, PINK1 and Parkin, normally work together i

250 2%), often in the context of Leigh syndrome; parkinsonism predominated in 13 adult patients (43%), am

251 , cause forms of frontotemporal dementia and parkinsonism, proving that dysfunction of tau is suffici

252 ndrome (KRS) characterized by juvenile-onset parkinsonism, pyramidal signs and dementia.

253 (PARK9) and characterized by juvenile-onset parkinsonism, pyramidal signs, and cognitive decline.

254 t nigral cell counts correlate strongly with parkinsonism ratings may explain discordant results betw

255 of childhood (AHC), and rapid-onset dystonia parkinsonism (RDP) are caused by mutations of Na(+),K(+)

256 lysis, we previously derived and validated a parkinsonism-related metabolic pattern (PRP) in nonhuman

257 significantly over 30 years in men for both parkinsonism (relative risk [RR], 1.17 per decade; 95% C

258 hort, and mortality rates among persons with parkinsonism remained stable.

259 These results suggest that DJ-1-associated Parkinsonism results from excessive protein glycation an

260 or older, incidence rates increased for both parkinsonism (RR, 1.24 per decade; 95% CI, 1.07-1.44) an

261 eral sclerosis in parkinsonism (0.2%), 1 had parkinsonism secondary to surgery (0.2%), and 84 remaine

262 In Parkinsonism, subthalamic nucleus (STN) neurons and two

263 obable multiple system atrophy-of either the parkinsonism subtype (MSA-P) or the cerebellar ataxia su

264 dopaminergic neurons from the patients with parkinsonism, suggesting that noninhibitory small-molecu

265 patients (patients without neurodegenerative parkinsonism syndromes and normal SPECT imaging) were in

266 ased, prospective cohort study of idiopathic parkinsonism that included patients diagnosed between Ja

267 nesis, ceruloplasmin knockout mice developed parkinsonism that was rescued by iron chelation.

268 m of 10 years and monitored for the onset of parkinsonism, the onset of dementia, or death, until Jan

269 c nervous system function and often signs of parkinsonism; the neuropathological hallmark of MSA is g

270 In the paraquat-induced model of Parkinsonism, this nigro-vagal pathway was compromised d

271 d up until January 1, 2015, for the onset of parkinsonism through serial in-person examinations and c

272 levance of mechanisms of autosomal recessive parkinsonism to sporadic PD has long been debated.

273 the association of a severe DOPA-responsive parkinsonism together with DOPA-unresponsive gait disord

274 bute to the skewing of the sex prevalence of parkinsonism toward women in this country, warranting fu

275 e following search terms: Parkinson disease, parkinsonism, tremor, postural instability and gait diff

276 Parkinsonism typified by sporadic Parkinson disease is a

277 ncluded in vivo behavioral measures of motor parkinsonism using a validated nonhuman primate rating s

278 uding motor subtype (multiple system atrophy-parkinsonism versus multiple system atrophy-cerebellar a

279 ienced a more rapid decline in her gait with parkinsonism, visual difficulties with restricted vertic

280 sex-matched Olmsted County resident without parkinsonism was also identified.

281 Parkinsonism was defined as the (1) presence of hypokine

282 e overall age- and sex-adjusted incidence of parkinsonism was lower in the 2000 subcohort (incidence

283 Recently, a new form of familial parkinsonism was reported to occur as a result of mutati

284 Parkinsonism was the most prevalent extrapyramidal movem

285 Multiple system atrophy-parkinsonism was the predominant subtype in 430 patients

286 Using experimental mouse models of Parkinsonism, we report here that global p11 knockout (K

287 onally relevant morphological alterations in parkinsonism, we used a combination of light and electro

288 Risk factors for primary dementia and parkinsonism were generally similar, except for a notabl

289 of DBS in the refined and standard model of parkinsonism were very different despite minimal behavio

290 ng of the pathways is altered in symptomatic parkinsonism, where iMSNs fire significantly more and ea

291 Some carriers have early-onset parkinsonism, whereas others remain asymptomatic despite

292 6) scores were each associated with incident parkinsonism, whereas the association with word learning

293 ke in 7 non-DLB subjects (3 with concomitant parkinsonism) who had normal (123) I-MIBG myocardial upt

294 After induction of parkinsonism with 1-methyl-4-phenyl-1,2,3,6-tetrahydropy

295 s a cause of autosomal-recessive early-onset parkinsonism with a distinctive phenotype of rapid and s

296 syndrome (KRS), characterized by early-onset Parkinsonism with additional neurological features.

297 multiplications were identified in familial parkinsonism with dementia.

298 at kinase 2 (LRRK2) cause autosomal-dominant Parkinsonism with pleomorphic pathology including deposi

299 She experienced worsening of parkinsonism with severe dyskinesias, and underwent subt

300 X-linked parkinsonism with spasticity (XPDS) presents either as t

301 Clinically, the condition manifests as parkinsonism with the addition of progressive balance, s

302 y are to determine the relationship of motor parkinsonism with the degree of injury to nigrostriatal

303 X-linked dystonia-parkinsonism (XDP) is a neurodegenerative disease associ